KRYSTAL BIOTECH DL-,00001

At the Cantor conference Krystal Biotech presented a scalable herpes‑simplex vector platform and emphasized that the company has reported positive EPS for three years and does not expect to need external funding for the pipeline. US sales for VYJUVEK have settled at about $85–95 million per quarter; international growth in Europe and Japan is expected to be the next driver within the next 12–18 months but faces pricing pressure and MFN uncertainties. Several clinical readouts (Hailey‑Hailey disease, ocular programs, lung cancer) are upcoming and could materially change the company’s profile. » Plus sur de.investing.com

Krystal Biotech’s stock rose to an all-time high of around $316.53, giving it a market capitalization of about $9.25 billion. Over the past year the stock gained 138.49%; InvestingPro currently rates it as slightly overvalued. Krystal reported a strong first quarter with earnings per share of $1.83 (expectation $1.48) and revenue of $116.4 million, beating both BofA and consensus estimates; BofA nonetheless marginally cut its price target from $325 to $323 and confirmed its buy recommendation. » Plus sur de.investing.com

Krystal Biotech reported Q1 2026 EPS of $1.83 (estimate $1.48) and revenue of $116.4 million, with both metrics beating expectations. Net income rose 56.6% to $55.9 million and gross margin improved to 95%. The stock fell about 2.3% in premarket trading despite the results. For Q2 and Q3 2026 the company guides to EPS of $1.86 and $2.21 and revenues of $126.45 million and $142.5 million, but cites risks from price negotiations in Europe, higher operating costs and potential market saturation in the US. » Plus sur de.investing.com